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Objective: We sought to characterize TLR activation across
multiple immune cell subsets and subjects, with the goal of
establishing a reference framework against which to compare
pathologic processes.
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CD1c1 DC: Conventional dendritic cell
CREB: cAMP response element–binding protein
MCP-1: Monocyte chemotactic protein 1
MIP-1b: Macrophage inflammatory protein 1b
MyD88: Myeloid differentiation primary response gene 88
NF-kB: Nuclear factor k light chain enhancer of activated B cells
NK: Natural killer
PAM: Synthetic di (PAM2) or tri (PAM3) acylated lipoprotein
pDC: Plasmacytoid dendritic cell
PRR: Pattern recognition receptor
R848: Resiquimod
SLE: Systemic lupus erythematosus
TIR: Toll/IL-1 receptor
TLR: Toll-like receptor
TRIF: TIR domain–containing adaptor inducing IFN-b
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O’GORMAN ET AL 1327autoimmune disease altered baseline cytokine production; newly
diagnosed untreated SLE patients shared a distinct monocytic
chemokine signature, despite clinical heterogeneity.
Conclusion: Mass cytometry defined a systems-level reference
framework for human TLR activation, which can be applied to
study perturbations in patients with inflammatory diseases,
such as SLE. (J Allergy Clin Immunol 2015;136:1326-36.)
Key words: Mass cytometry, Toll-like receptors, systemic lupus
erythematosus, inflammation, monocytes, monocyte chemotactic
protein 1
Pattern recognition receptors (PRRs) recognize conserved
features of foreign microorganisms during infection and
self-molecules in tissue injury.1,2 Toll-like receptors (TLRs)
were the first identified family of PRRs; the human genome
encodes 10 TLRs.3,4 TLRs are type 1 transmembrane receptors
with an extracellular ligand–binding domain, a transmembrane
domain, and a cytoplasmic Toll/IL-1 receptor (TIR) domain.3,5
TLRs are expressed on the plasma membrane (TLR1, TLR2,
and TLR4-TLR6) or in endosomes (TLR3 and TLR7-TLR9).6
Ligand binding to TLRs induces dimerization of the TIR
domains. This dimer functions as a scaffold for myeloid
differentiation primary response gene 88 (MyD88) or TIR
domain–containing adaptor inducing IFN-b (TRIF) protein
adaptor complexes, which then activatemitogen-activated protein
kinase and nuclear factor k light chain enhancer of activated B
cells (NF-kB) pathways or interferon regulatory factors,
respectively.7,8 Crosstalk with other pathways elicits the
production of inflammatory and regulatory cytokines that shape
adaptive immunity.9 Although TLR-induced inflammation is
important for antimicrobial responses, inappropriate TLR
recognition of self-molecules results in development of
autoimmune diseases, such as systemic lupus erythematosus
(SLE).10,11 In patients with SLE, self-nucleic acid–containing
antibodies form immune complexes that can sequentially activate
Fcg and endosomal TLR receptors.12-14
TLR signaling and cytokine production are precisely regulated
at multiple levels to maintain the balance between protective
immunity and inflammatory disease. First, the cellular
compartmentalization of TLRs limits their accessibility to
ligands. Second, different immune cell populations selectively
express certain TLRs and TLR-inducible signaling pathways.15
Finally, each immune cell subset produces a distinct set of
cytokines. Systems-scale proteomic approaches have previously
been applied to characterize this level of complexity of TLR
networks. For example, mass spectrometry–based phosphopro-
teomic analysis was used to profile TLR-induced signaling in
murine macrophages.16,17 A separate study applied mass
spectrometry–based secretomic analysis to evaluate cytokine
production elicited by TLR activation in murine macrophages
and dendritic cells.18,19 Although informative, these studies
have provided global views of TLR signaling and cytokine
production in specific immune cell subsets but not within the
context of an integrated cellular immune system with
single-cell resolution.
To achieve a systems-level perspective of TLR biology that
simultaneously accounts for functional diversity at the single-cell
level, the activation of intracellular signaling pathways, and
cytokine production, we capitalized on the ability of mass
cytometry to capture this complexity. Here, 40-parameter masscytometry was used to define a reference framework for human
TLR activation ex vivo in whole blood samples. The application
of this framework to evaluate cytokine alterations in a systemic
inflammatory disease, such as SLE, revealed a characteristic
abnormal monocytic chemokine signature in patients with SLE
in the basal state in the absence of any ex vivo stimulation. This
study demonstrates the utility of this approach to characterize
TLR activation across the immune system and in patients with in-
flammatory diseases in general.METHODS
Study participants
All human donors were enrolled under a study protocol approved by the
Institutional Review Board of the Research Compliance Office at Stanford
University.Written informed consent was obtained from all study participants.
Inclusion/exclusion criteria for healthy volunteer donors and patients with
SLE can be found in the Methods section and Table E1 in this article’s Online
Repository at www.jacionline.org. Patients with SLE fulfilled the revised
American College of Rheumatology diagnostic criteria (see Table E2 in this
article’s Online Repository at www.jacionline.org).20Sample processing, stimulation, and cytometric
analysis
Donor whole blood was collected in heparinized vacutainers (BD, Franklin
Lakes, NJ), incubated at 378C with TLR ligands21 (see Table E3 in this arti-
cle’s Online Repository at www.jacionline.org), fixed, and permeabilized
for intracellular staining. Conditions for signaling proteins and intracellular
cytokine stainingwere adapted from previous studies (see theMethods section
in this article’s Online Repository).22,23 Clone, vendor, and conjugation
information for all mAbs are shown in Table E4 in this article’s Online
Repository at www.jacionline.org. Cells were analyzed on a CyTOF
instrument (Fluidigm, South San Francisco, Calif). Data were acquired by
using internal metal isotope bead standards, normalized, and analyzed as
previously described (FlowJo software; TreeStar, Ashland, Ore and Cytobank,
Mountain View, Calif).24,25‘‘Signaling network heatmap’’ visualization tool
In brief, for each experimental condition and cell type population,
representative single cells were sampled and ordered from lowest to highest
transformed value for each signaling protein. Subtractions between stimulated
and unstimulated conditions yielded single-cell signaling fold changes,
which were colored and packed together into a signaling node. See the
FIG 1. Mass cytometry identifies major immune cell subsets in human whole blood. After fixation and RBC
lysis, cells were labeled with 22 surface markers that defined 11 general cell types. The extended T-cell
gating strategy is shown in Fig E1. Subsequently, cells were permeabilized, stained with mAbs that probe
intracellular proteins (see Table E4), and analyzed by means of mass cytometry. Representative data from
1 healthy donor are shown. ODN, Oligodeoxynucleotide; pERK, phosphorylated extracellular
signal-regulated kinase; pHH3, phosphorylated histone H3; pTBK1, phosphorylated TANK-binding kinase 1.
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and visualization development.CD14hi monocytes combinatorial cytokine heatmap
In brief, cytokine positivity was determined in a binary fashion based on the
95th percentile intensity threshold; CD14hi monocyte subpopulations express-
ing different cytokine combinations were clustered based on similar cytokine
response profiles induced by TLR ligands. See the Methods section in this
article’s Online Repository for data processing and computational design.Statistical analysis of CD14hi monocyte cytokine
signatures
Comparison of the mean percent positivity (defined by the 95th percentile
threshold as above) for each monocytic cytokine between the SLE and healthy
control groups was performed by applying a Student t test with Bonferroni
adjustment, which apportions the significance level evenly among the 9
hypothesis tests (P 5 .0056, adjusted significance level; Microsoft
Excel 2011).RESULTS
Mass cytometry identifies major immune cell
subsets in human whole blood
By using a priori knowledge about hematopoietic lineages,
human blood cells were categorized into 11 major immune
cell subsets (Fig 1 and see Fig E1 in this article’s Online
Repository at www.jacionline.org). Granulocytes, B cells, and
T cells were classified based on surface marker expression of
CD66, CD19/CD20/HLA-DR, and CD3, respectively.22
CD32CD192HLA-DR2CD71 lymphocytes26 were subdivided
into CD16hi and CD56hi natural killer (NK) cell subsets.27CD11c and HLA-DR coexpression defined nongranulocytic
myeloid cells.28 CD11cloHLA-DRhiCD1231 cells were classified
as plasmacytoid dendritic cells (pDCs).29 CD11c1HLA-DR1
monocytes were subdivided into CD14hi (classical) and CD16hi
(nonclassical) subsets.30 CD1c expression defined conventional
dendritic cells (CD1c1 DCs),28 and FcεRI and CD123
coexpression identified basophils.31 TLRs, their ligands,
signaling pathways, and cytokines examined are listed in Fig 1.A signaling network heatmap visualization tool
provides an integrated view of TLR signaling
patterns
Changes in the activation states of 9 signaling proteins were
monitored in 11 cell subsets in response to 8 stimuli.
Conventional depiction of such high-density data with
2-dimensional plots, histograms, or heatmaps does not capture
an integrated view of all the measured parameters nor does it
make the most of the single-cell resolution. A signaling network
heatmap visualization tool was developed to overcome this
analytic challenge. In brief, up to 1000 representative single cells
were sampled from each immune cell subset and TLR stimulus
condition. For each cell type and condition, cells were ordered by
expression value for every signaling protein indexed from lowest
to highest arcsinh transformed value. The arcsinh scale, a
bioexponential transformation used with flow cytometric data,
was chosen over a traditional log scale to account for negative
values.32 For each cell type and signaling protein, expression
values for that signaling protein in the stimulated and
unstimulated conditions were paired according to their indexed
transformed value. Differences between these paired values
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were colored according to the arcsinh difference (Fig 2, B) and
arranged into a signaling node (Fig 2, C) based on their original
index position. These signaling nodes were then arranged into
pathways downstream of MyD88 and TRIF adaptor protein
complexes (Fig 2, D). The generalized pathways include NF-kB
and activator protein 1 activation, as well as proteins involved
in downstream transcriptional and translational regulation (for
further details, see the Methods section in this article’s Online
Repository). Signaling network heatmap and variance data from
other donors are shown in Figs E2 and E3 in this article’s Online
Repository at www.jacionline.org, respectively.Systems-level TLR signaling analysis demonstrates
diverse signaling responses in myeloid cell subsets
and selective NF-kB activation in NK and T-cell
subsets
In the myeloid lineage the induction of every measured
signaling protein was observed in more than 95% of CD14hi
and CD16hi monocytes in response to all extracellular TLR
ligands and the endosomal TLR7/8 ligand resiquimod (R848;
15- to 100-fold increases with marginal activation of
phosphorylated extracellular signal-regulated kinase; Fig 2, E).
Although pDCs only responded to endosomal stimuli, CD1c1
DC TLR signaling responses largely overlapped with monocytic
signaling responses, with the exception of zymosan. Zymosan
induced IkBa degradation in both CD1c1 DCs and CD14hi
monocytes. However, zymosan also activated multiple other
signaling pathways in CD14hi monocytes. This difference is
potentially due to the fact that CD1c1 DCs express TLR2 only,
whereas CD14hi monocytes express both TLR2 and dectin-1
receptors.33 Like CD1c1 DCs, granulocytes responded to all
extracellular ligands and R848 (Fig 2, E). In contrast, only a
fraction of basophils responded to PAM2 (TLR2/6 ligand;
15.5% responders) and LPS (TLR4 ligand; 7.2% responders)
with induction of IkBa degradation and p38 phosphorylation
(Fig 2, E). This restricted basophil-signaling profile is concordant
with previous studies on the roles of TLR2- and TLR4-mediated
basophil activation in augmenting allergic reactions.34
In the lymphoid lineage endosomal TLR agonists induced
NF-kB and cAMP response element–binding protein (CREB)
pathways in B cells (Fig 3, A, and see Fig E4 in this article’s
Online Repository at www.jacionline.org). Unexpectedly, the
TLR2 ligands PAM2 (TLR2/6) and PAM3 (TLR1/2) selectively
activated the NF-kB pathway in NK and T-cell subsets (Fig 3,
B and C). In approximately one third of CD56hi NK cells, IkBa
degradation (36.6% responders) was observed in response to
PAM2 stimulation (also phosphorylation of pCREB and p38;
see Fig E5, A, in this article’s Online Repository at
www.jacionline.org). A lower frequency of CD56hi NK cells
(20.1%) responded to PAM3 stimulation (see Fig E5, A). These
responses were far less apparent in CD16hi NK cells (Fig 3, B,
and see Fig E5, B). PAM2 and PAM3 stimulations were
performed in 10 additional donor blood samples, resulting in
IkBa degradation in 36% (SD, 12.67%) and 24.3% (SD, 17%)
of CD56hi NK cells, respectively (see Fig E5, B), to assess the
reproducibility of this observation. NK cells were enriched to
approximately 96.75% purity (see the Methods section in this
article’s Online Repository) and stimulated with PAM2 and
PAM3 to understand this further. IkBa degradation was mainlyobserved in the CD56hi NK population in response to PAM2,
suggesting that this TLR ligand directly activated these
cells (see Fig E6 in this article’s Online Repository at
www.jacionline.org).
As observed for NK cells, PAM2 and PAM3 stimulation also
activated the NF-kB pathway in CD4 T cells (Fig 3, C). This
activity was even less apparent in CD8 T cells (Fig 3, C, and
see Fig E7, A, in this article’s Online Repository at
www.jacionline.org). In a group of 10 additional donors, an
average of 14.5% (SD, 5.1%) and 11.9% (SD, 7.8%) CD4 T cells
responded to PAM2 and PAM3, respectively (see Fig E7, B). To
investigate whether PAM2 and PAM3 directly activated T cells,
T cells enriched to approximately 96% purity were stimulated
with these ligands, and exclusive NF-kB pathway induction
was observed in similar percentages of cells (average of
14.03% and SD of 5.1% for PAM2 and average of 4.32% and
SD of 5.1% for PAM3; see Fig E7, C), indicating that these
lipopeptides are acting directly on T lymphocytes. Although
previous studies have explored the role of TLR2 agonists in
T-cell activation,35,36 activation of specific signaling pathways
has not been well defined.TLR-induced cytokine signatures demonstrate cell
type and TLR ligand specificity
Production of 16 cytokines downstream of the signaling
pathways examined above was simultaneously measured in
myeloid and lymphoid cell types (Fig 1). Cytokine data were
analyzed by using a Boolean gating strategy, with positivity
defined in Fig E8 in this article’s Online Repository at
www.jacionline.org. TLR stimulation induced the production of
10 of 16 cytokines in 1 or more myeloid cell populations, with
minimal cytokine production in lymphoid cells (Fig 4 and see
Fig E9 in this article’s Online Repository at www.jacionline.org).
Mirroring TLR-induced signaling patterns, CD14hi monocyte
and CD1c1 DC cytokine response profiles also largely
overlapped (Fig 4 and see Fig E10 in this article’s Online
Repository at www.jacionline.org). However, CD1c1 DCs
consistently produced more IL-12 (35.7% more, averaged over
all TLR ligand conditions) after stimulation than did CD14hi
monocytes (see Fig E10). LPS and R848 induced different
chemokine responses in CD14hi monocytes, and LPS elicited
IL-8 production in the absence of monocyte chemotactic protein
1 (MCP-1) expression, whereas R848 induced the converse
(Fig 4). CD16hi monocytes were not included in the cytokine
analysis because after the 6-hour stimulation period, CD16 was
shed from nonclassical monocytes.
Unlike monocytes and CD1c1 DCs, pDCs demonstrated a
restricted cytokine response repertoire, primarily IFN-a
production in response to endosomal TLR agonists (Fig 4).
Granulocytes and basophils produced macrophage inflammatory
protein 1b (MIP-1b), IL-8, and IL-1 receptor antagonist only (see
Fig E9, A). Minimal cytokine production was observed in the
lymphoid compartment (see Fig E9, B), even for B cells, in which
endosomal TLR stimulation induced signaling responses (Fig 3,
A). Despite the PAM2- and PAM3-driven NF-kB signaling
activation observed in NK and T-cell subpopulations (Fig 3, B
and C), cytokine responses were not induced in these cells
(see Fig E9, B), suggesting that these TLR ligands play a
costimulatory role in antigen receptor activation.
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=FIG 3. Signaling network heatmap demonstrates selective NF-kB activation
in subsets of NK and T cells. A, B cells respond to endosomal stimuli with
induction of the NF-kB pathway and CREB phosphorylation. B and C, Trace
populations of NK cells (Fig 3, B) and T cells (Fig 3, C) responded to PAM2
and PAM3, with induction of the NF-kB pathway. Representative data from
1 healthy donor are shown. For the complete lymphoid single-cell heatmap,
see Fig E4. For additional experiments involving purified NK and T-cell
populations and their TLR2 responses from additional donors,
see Figs E5-E7. ODN, Oligodeoxynucleotide; pERK, phosphorylated
extracellular signal-regulated kinase; pHH3, phosphorylated histone H3;
pS6, phosphorylated ribosomal S6 kinase; pTBK1, phosphorylated
TANK-binding kinase 1.
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signatures in CD14hi monocytes
Combinatorial cytokine production is the ability to produce
numerous combinations of cytokines simultaneously. T cells haveFIG 2. A signaling network heatmap visualization to
patterns. A,Up to 1000 representative cells were sample
(unstim) and stimulated (stim) conditions. Cells we
transformed value for each signaling protein. Co
unstimulated and stimulated cells were subtracted
signaling fold changes. B, These single-cell signaling fo
as the cells from which they were derived and co
degradation), according to their arcsinh difference val
according to their index number from lowest to highe
to form a signaling node. C, Signaling nodes demons
population. The center of the node corresponds to the
corresponds to the highest values. Model activation pa
in a signaling network module, reflecting a generalize
whole blood was stimulated with the TLR ligands ind
stained, analyzed, and classified as described in Fig
and organized as described above. Signaling data fro
and variances from other sampled donors are show
pERK, phosphorylated extracellular signal-regulated
phosphorylated ribosomal S6 kinase; pTBK1, phosphobeen shown to exhibit combinatorial polyfunctional cytokine
responses that are correlated with resistance to disease.37,38 How-
ever, it is not clear whether myeloid cell populations share this
capability. In this study CD14hi monocytes produced the most
diverse cytokine responses to TLR stimulation (Fig 4 and see
Fig E10). Only subsets with a minimum 1% population
frequency were included in the analysis to emphasize salient
polyfunctional combinations. Here we found that 83 of the
possible 512 combinations meet that threshold (Fig 5). Hierarchic
clustering of these cytokines into a combinatorial heatmap
exposed relationships between coexpressed cytokines (Fig 5,
left panel) and between TLR stimuli that elicit similar cytokine
responses (Fig 5, right panel). IL-1b and MIP-1b behaved the
most similarly, and the proinflammatory cytokines IL-12 and
TNF-a formed a separate cluster.
PAM2, PAM3, and flagellin elicited similar cytokine profiles;
generally, 2 or 3 cytokines were expressed, primarily IL-1b,
MIP-1b, and IL-8 (Fig 5, right panel). LPS and zymosan also
induced similar combinatorial cytokine signatures, likely related
to the synergistic effects of dectin-1 with TLR2 and TLR4.33
R848 and LPS induced comparable monocytic polyfunctionality
(Fig 5, right panel) but differed in the type of cytokines induced
(Fig 5, left panel). These cytokine combinatorial phenotypes
suggest a monocytic functional specialization that cannot be
defined by surface marker–based classifications alone.CD14hi monocytes from patients with SLE show an
inflammatory cytokine signature typified by MCP-1
Intraindividual and interindividual variabilities in healthy
donors were determined to assess the reproducibility of this
approach for evaluating TLR-induced cytokine production.
Monocytic TLR-induced cytokine patterns were highly
conserved over time for a single donor (Fig 6, A) and among 9
healthy donors (Fig 6, B). The least degree of intraindividual
and interindividual variability was observed for MIP-1b
production, with the SD ranging from 1.02% (LPS) to 5.25%
(R848) for 1 donor over time and 0.41% (R848) to 4.44%
(LPS) among 9 donors (see Fig E11 in this article’s Online
Repository at www.jacionline.org). IL-12 production varied
most, with an SD of 13.3% for 1 donor longitudinally and
18.2% for 9 donors in the R848 condition (see Fig E11). These
results demonstrate the reproducibility of this experimentalol provides an integrated view of TLR signaling
d for each cell type population and for unstimulated
re ordered from the lowest to highest arcsinh
rresponding single-cell arcsinh values between
on a pairwise basis, which constitute single-cell
ld changes are indexed in the same numbered order
lored in red (phosphorylation) or blue (protein
ue. Single-cell signaling fold changes are arranged
st, starting from the inside and moving clockwise
trate the distribution of responsive cells in a given
lowest values of the histograms, and the periphery
tterns are shown. D, Signaling nodes are organized
d structure of TLR response pathways. E, Human
icated in Fig 1. After stimulation, cells were fixed,
1. Single-cell signaling fold changes were derived
m 1 healthy donor are shown; additional donors
n in Figs E2 and E3. ODN, Oligodeoxynucleotide;
kinase; pHH3, phosphorylated histone H3; pS6,
rylated TANK-binding kinase 1.
FIG 4. TLR-induced cytokine signatures demonstrate TLR agonist and cell type specificity. Human whole
blood was stimulated with PAM2, LPS, and R848 for 6 hours in the presence of protein secretion inhibitors.
Monocytes (Monos) and dendritic cells were identified, as indicated in Fig 1. Cells demonstrating cytokine
production levels greater than the 95th percentile of unstimulated cells were defined as cytokine positive
(see Fig E8). Cytokine signatures are presented as radar plots with 20% radial intervals. Cytokines are
arranged in functional families in clockwise order: IL-1 family (IL-1a, IL-1b, and IL-1 receptor antagonist),
proinflammatory cytokines (IL-6, IL-12, TNF-a, and IFN-a), and chemokines (MIP-1b, MCP-1, and IL-8).
Average values based on responses from 9 healthy donors are shown. Cytokine variance data are shown
in Fig E11.
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induced cytokine profiles in healthy donors. This reference frame-
work was used to compare cytokine profiles in patients with an in-
flammatory disease in which abnormal TLR responses drive
pathologic cytokine production, such as SLE.39,40
Analysis of blood samples from 8 patients with newly
diagnosed, untreated, and clinically heterogeneous SLE (see
Table E2) revealed a common abnormal CD14hi monocytic
cytokine signature in the basal state in the absence of ex vivo
stimulation (Fig 7). Ninety-fifth percentile baseline thresholds
(see Fig E7) for all cytokines were defined based on an initial
time point when blood was immediately processed after draw
(time zero, see Fig E10) to internally control these experiments.
CD14hi monocytes from each of the 8 patients with newly
diagnosed and untreated SLE exhibited increased MCP-1 levels
(average, 82.6%; SD, 9.7%; see Fig E8) after 6 hours of secretion
block in the absence of any stimulation. Under these conditions,
MCP-1 levels in corresponding healthy control subjects (different
healthy donors than those in Fig 6) did not change to the same
extent (average, 18.8%; SD, 8.1%; see Fig E12 in this article’s
Online Repository at www.jacionline.org). MCP-1 is an inducible
proinflammatory chemokine involved in the immunopathogene-
sis of human and murine lupus nephritis.41 In murine SLEmodels
MCP-1 inhibition ameliorates lupus nephritis.42 Previous studies
and our data indicate that MCP-1 holds promise as a therapeutic
target.42-45
Levels of other cytokines, such as MIP-1b and TNF-a, were
also increased in samples from patients with newly diagnosed and
untreated SLE compared with those in healthy donor samples
(Fig 7 and see Fig E13 in this article’s Online Repository at
www.jacionline.org). Bonferroni-adjusted t test calculation
comparing the average expression of each cytokine between the
SLE and healthy control groups confirmed statistically significant
differences in MCP-1 (P 5 7.6E210), MIP-1b (P 5 .002), and
TNF-a (P 5 .001) levels. Comparison of cytokine profiles for
all 11 cell subsets (as in Fig 1) for all 8 SLE versus healthy
matched control pairs did not demonstrate any statistically
significant differences other than those observed in CD14hi mono-
cytes (data not shown). Although all samples from patients with
SLE demonstrated this common monocytic cytokine signature
(MCP-1,MIP-1b, and TNF-a) based on single cytokine positivity(Fig 7), patients’ combinatorial cytokine profiles differed (see Fig
E14 in this article’s Online Repository at www.jacionline.org).
In this study, using a systems-scale single-cell proteomic
approach to characterize human TLR signaling and cytokine
networks, we defined a reference framework that can be applied
to study alterations in these parameters in patients with
inflammatory disease.DISCUSSION
TLRs (and other PRRs) are involved in the complex balance
between protective immunity and inflammatory disease. To
elucidate how TLR networks calibrate innate and adaptive
immune responses to maintain this balance, we have used
high-dimensional mass cytometry to broadly measure
intracellular signaling responses and cytokine profiles in healthy
subjects and patients with newly diagnosed and untreated SLE.
This comprehensive TLR activation analysis in healthy
subjects corroborates previous findings in TLR biology and
reveals novel TLR signaling responses in NK and T cells.
A signaling network heatmap visualization tool (Fig 2, A-D)
was developed to depict these TLR-induced signaling patterns
with single-cell resolution. This method enables display of the
activation characteristics of 9 signaling proteins in 11 cell subsets
in response to 8 TLR ligands, with more than 600 features and
approximately 2 million data points in Fig 2, E. This is a scalable
tool to visualize high-dimensional data sets that provides a
framework through which the signaling biology of entire receptor
systems can be explored with nearly single-cell resolution.
Although TLR responses have been extensively investigated in
myeloid cells, they are not well defined in the lymphoid lineage,
with the exception of B cells.46 In our analysis only TLR2 and
TLR5 ligands activated signaling, primarily in CD56hi NK cells
(Fig 3, B). TLR2-dependent NK cell activation has been linked
to poxvirus and mycobacterial immunity.47,48 Notably,
TLR2-mediated mycobacterial recognition promotes NK
cell–DC cross-talk and IL-12 production,49 but it is unclear
whether TLR2 stimuli directly activated NK cells. It is unlikely
that the observed signaling responses (Figs 2, E, and 3) were
indirect (paracrine) in nature, given a 30-minute incubation;
however, indirect effects cannot be completely excluded.































































































































































































































































































































































IL−12 TNFα IL−6 IL−1a IL−8 IL−1β MiP1β IL−1RA MCP1
Cytokine Combinations CD14hi Monocyte Polyfunctionality
FIG 5. TLR ligands induce diverse combinatorial cytokine signatures in CD14hi monocytes. CD14hi
monocyte combinatorial cytokine polyfunctionality was assessed in response to 8 TLR ligands listed in
Fig 1. A Boolean gating script was used to quantify subgroup frequency based on a 95th percentile threshold
(see Fig E8). Cytokine combinations are represented as rows on the left panel, with blue dots indicating
positivity for a particular cytokine. For a 9-cytokine analysis, 512 possible combinations of coexpressed
cytokines are possible. Only cytokine combinations expressed by more than 1% of cells are depicted; 83
different cytokine combinations were detected at this level and above. Red color scaling indicates the
frequency of each CD14hi monocyte subpopulation. Hierarchic clustering of cytokines and TLR ligands
relate cytokine coexpression patterns (left panel) and cytokine combination patterns shared between TLR
ligands (right panel), respectively. Data from 1 healthy donor are shown.
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FIG 6. Intraindividual and interindividual reproducibility of TLR-induced cytokine signatures in healthy
donor CD14hi monocytes. A, Thin lines relate longitudinal monthly blood draw samples for 1 healthy donor.
Bold lines relate the average of all 4 samples. B, Thin lines are specific to each distinct healthy donor. Bold
lines represent the average of all 9 healthy donor cytokine responses.
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1334 O’GORMAN ET ALTherefore purified cell populations were assayed to evaluate
noncanonical TLR ligand responses in NK cells and T cells.
Here we found that an enriched NK cell population responded
to TLR2 ligands within 30 minutes, showing that NK cells can
directly respond to these ligands (see Fig E6).
Similarly, TLR responses in T cells are also poorly described.
A subset of CD4 T cells degraded IkBa after TLR2 stimulation
(Fig 3,C), but this did not lead to cytokine production (see Fig E9,
B). This pathway selectivity and the inability of TLR2 ligands
alone to induce cytokine production in T cells suggest a
costimulatory role for TLR2 in T-cell activation. This observation
is consistent with and might provide a molecular mechanism for
previous reports that mycobacterial ligands and the live BCG
vaccine enhance T-cell proliferation and cytokine production
only when coupled with T-cell receptor engagement.36,50 These
results also suggest that microbial lipopeptides should be
explored as adjuvants in vaccine design. Detailed NK cell and
T-cell phenotyping could be incorporated in future studies to
further understand this isolated signaling response to TLR2
ligands.
TLR activation was tracked from signal transduction to cytokine
production, demonstrating how different TLR agonists elicited
distinct cytokine combinations across the immune system. To
construct a systems-level TLR activation reference framework, we
compared TLR-induced cytokine responses longitudinally in a
single donor and among healthy donors. Minimal intraindividual
and interindividual variability (Fig 6) suggested the applicability of
this framework to study an inflammatory disease, such as SLE.
Compared with monocytes from healthy control subjects, CD14hi
monocytes from 8 patients with newly diagnosed and untreatedSLE exhibited a statistically significant distinct cytokine signature
(MCP-1, MIP-1b, and TNF-a) at the basal state, with the most
prominent and uniform of the cytokines being MCP-1 (Fig 7 and
see Fig E13). These 8 patients with SLEmanifested diverse clinical
symptoms (see Table E2), which is characteristic of this complex
autoimmune disorder. Yet, significantly, by using our analysis sys-
tem, they all expressed this cytokine signature, particularlyMCP-1,
suggesting that they shared an underlying basis that could be useful
in both diagnosis and treatment.Additionally, these patient samples
were obtained before any immunomodulatory treatment, and thus
there was no heterogeneity introduced by drug treatments.
MCP-1 (also known as CCL2) recruits monocytes and
lymphocytes to sites of inflammation.45 Increased MCP-1 levels
have been detected in patients with a variety of autoimmune
disorders51-53 and often correlate with disease activity.43,45,54
MCP-1 might play a critical role in autoimmune end-organ
damage, and MCP-1 neutralization has been shown to ameliorate
disease in rodent models of SLE.42 The mechanism responsible
for increased MCP-1 production in patients with SLE is unclear,
but available data suggest several possibilities.
First, MCP-1 is a known type I interferon inducible
chemokine.55 Multiple transcriptomic studies have observed an
IFN-a signature in patients with SLE, likely induced by nucleic
acid–containing immune complexes activating endosomal TLRs
in pDCs12,56 and possibly leading to MCP-1 induction. Second,
Fcg receptor activation elicits monocytic MCP-1 production,57
and thus circulating immune complexes in patients with SLE
could explain MCP-1 induction.14 Finally, although
RNA-containing immune complexes in patients with SLE might
activate TLR8 in monocytes, leading to MCP-1 production,
Healthy matched controls SLE patients
SLE #1 SLE #2 SLE #3 SLE #4
CD14hi Monocytes, 6 hours Incubation with Protein Transport Inhibitor, No stimulation

































































FIG 7. CD14hi monocytes from patients with SLE show an inflammatory chemokine signature typified by
MCP-1. Cytokine positivity was defined based on the 95th percentile threshold of blood processed
immediately after draw (time zero) and thus were internally controlled. Each radar plot represents the
CD14hi monocytic cytokine signature of a patient with SLE (red line) versus a healthy sex-matched control
subject (blue line) after a 6-hour incubation period with protein secretion inhibitor (no exogenous stimuli).
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O’GORMAN ET AL 1335monocytic cytokine profiles from patients with SLE did notmatch
R848-induced cytokine profiles, making this explanation
unlikely. Regardless of the cause of MCP-1 production, MCP-1
neutralization could potentially serve as an anti-inflammatory
adjunctive therapy to reduce the use or dosage of cytotoxic
immunosuppressive drug regimens that are necessary to
control SLE.
In conclusion, mass cytometry was used to generate a
comprehensive reference framework of human TLR-driven
immune responses in myeloid and lymphoid lineages. Analysis
of samples from patients with SLE demonstrated that this
reference framework could be applied to study inflammatory
disease. Additionally, this study establishes a paradigm for using
high-dimensional single-cell proteomic approaches to generate
reference maps of other receptor systems.
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